Adamis Pharmaceuticals Corporation (ADMP) financial statements (2021 and earlier)

Company profile

Business Address 11682 EL CAMINO REAL
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
3/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 91917545
Cash and cash equivalents 91917445
Other undisclosed cash, cash equivalents, and short-term investments    1  
Receivables (0)(0)    
Inventory, net of allowances, customer advances and progress billings 2321 
Inventory 2321  
Prepaid expense 110000
Other current assets 000000
Other undisclosed current assets 2321  
Total current assets: 142621745
Noncurrent Assets
Finance lease, right-of-use asset 0
Operating lease, right-of-use asset 2
Property, plant and equipment 12107500
Intangible assets, net (including goodwill) 19212326810
Goodwill 8888  
Intangible assets, net (excluding goodwill) 11131618810
Deposits noncurrent assets 00000 
Other noncurrent assets 22    
Total noncurrent assets: 34333031810
TOTAL ASSETS: 485851381215
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 786411
Accounts payable 443201
Accrued liabilities 222200
Employee-related liabilities  1100 
Deferred revenue 1
Debt 3324 0
Deferred compensation liability      1
Deferred revenue and credits00  
Other liabilities     1 
Other undisclosed current liabilities  1  00
Total current liabilities: 10129933
Noncurrent Liabilities
Long-term debt and lease obligation 1 33  
Long-term debt, excluding current maturities   33  
Finance lease, liability 0
Operating lease, liability 1
Liabilities, other than long-term debt 0001  
Deferred tax liabilities, net001  
Deferred income tax liabilities 0
Total noncurrent liabilities: 2034  
Total liabilities: 1212121333
Stockholders' equity
Stockholders' equity attributable to parent 36474025912
Preferred stock    00 
Common stock 000000
Treasury stock, value (0)(0)(0)(0)(0)(0)
Additional paid in capital 2182001541147858
Accumulated deficit (182)(153)(114)(88)(69)(46)
Total stockholders' equity: 36474025912
TOTAL LIABILITIES AND EQUITY: 485851381215

Income statement (P&L) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
3/31/2014
Revenues 2215136  
Revenue, net136  
Cost of revenue
(Cost of Goods and Services Sold)
 (15)(10)(7)(5)  
Gross profit: 7562  
Operating expenses (36)(45)(30)(27)(14)(5)
Other undisclosed operating income      1
Operating loss: (29)(39)(25)(25)(14)(4)
Nonoperating income (expense) 00(1)10(4)
Investment income, nonoperating 0000 1
Interest and debt expense (0)(0)(0)(0) (9)
Other undisclosed income from continuing operations before equity method investments, income taxes    0  
Loss from continuing operations before equity method investments, income taxes: (29)(40)(26)(24)(14)(17)
Other undisclosed income from continuing operations before income taxes 000   
Loss from continuing operations before income taxes: (29)(39)(26)(24)(14)(17)
Income tax expense (benefit) (0)005  
Other undisclosed income from continuing operations      9
Net loss attributable to parent: (29)(39)(26)(19)(14)(8)
Preferred stock dividends and other adjustments    (1)  
Other undisclosed net income available to common stockholders, basic  78    
Net income (loss) available to common stockholders, basic: (29)39(26)(21)(14)(8)
Dilutive securities, effect on basic earnings per share     (0) 
Other undisclosed net loss available to common stockholders, diluted      (1)
Net income (loss) available to common stockholders, diluted: (29)39(26)(21)(14)(9)

Comprehensive Income ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
3/31/2014
Net loss: (29)(39)(26)(19)(14)(8)
Comprehensive loss, net of tax, attributable to parent: (29)(39)(26)(19)(14)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: